VOYAGER THERAPEUTICS INC (VYGR)

Voyager Reports Third Quarter 2024 Financial and Operating Results

- Enrollment and dosing complete in single ascending dose clinical trial of anti-tau antibody VY7523 for Alzheimer’s; on track to generate top-line data H1...

Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences

LEXINGTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing...

Voyager Therapeutics Announces Third Quarter 2024 Conference Call and Webcast

LEXINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing...

VYGR Crosses Above Key Moving Average Level

Notable Friday Option Activity: RILY, SAVE, VYGR

RSI Alert: Voyager Therapeutics (VYGR) Now Oversold

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LEXINGTON, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing...

Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences

LEXINGTON, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing...

Commit To Purchase Voyager Therapeutics At $5, Earn 13.9% Annualized Using Options

7 Biotech Stocks to Buy for Their Game-Changing Potential

Although the market may be reeling from the recent fallout, the red ink presents a viable opportunity in these biotech stocks.

Voyager Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase

LEXINGTON, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing...

VYGR Stock Earnings: Voyager Therapeutics Beats EPS, Beats Revenue for Q2 2024

VYGR stock results show that Voyager Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

VYGR Stock Earnings: Voyager Therapeutics Beats EPS, Beats Revenue for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Voyager Therapeutics (NASDAQ:VYGR) just reported results for the second quarter...

Voyager Therapeutics Reports Second Quarter 2024 Financial and Operating Results

- Top-line safety and pharmacokinetic data expected in H1 2025 from recently initiated single ascending dose trial of anti-tau antibody for Alzheimer’s...

Voyager Therapeutics Announces Second Quarter 2024 Conference Call and Webcast

LEXINGTON, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing...

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LEXINGTON, Mass., July 23, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing...

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LEXINGTON, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing...

VYGR Makes Notable Cross Below Critical Moving Average

Voyager Therapeutics to Present at Multiple Virtual Investor Conferences

LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing...

Voyager Therapeutics Announces Appointment of Nathan Jorgensen as Chief Financial Officer

LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing...

Voyager Therapeutics Breaks Below 200-Day Moving Average - Notable for VYGR

Voyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer’s Disease

LEXINGTON, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic...

VYGR Stock Earnings: Voyager Therapeutics Beats EPS, Beats Revenue for Q1 2024

VYGR stock results show that Voyager Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

VYGR Stock Earnings: Voyager Therapeutics Beats EPS, Beats Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Voyager Therapeutics (NASDAQ:VYGR) just reported results for the first quarter ...

Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results

- Company announces clearance of IND application with FDA for anti-tau antibody VY-TAU01 for the treatment of Alzheimer’s disease; expect to begin single...

Voyager Therapeutics Presents Data for Second-Generation, TRACER™-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting

- Translational potential of TRACER-derived AAV capsids demonstrated by data across multiple species (murine, porcine, multiple NHPs, human cells) and...

Voyager Therapeutics Announces First Quarter 2024 Conference Call and Webcast

LEXINGTON, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic...

Commit To Purchase Voyager Therapeutics At $5, Earn 12.4% Annualized Using Options

Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting

Spotlight on new, second-generation, TRACER™-derived AAV capsids; translatability as evidenced by cross-species and receptor data; and activity against...

Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment

LEXINGTON, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing...